Physician profile
Murray Stein
NPI 1659390771
$120,753.65
in general payments reported to CMS, 2019-2025
13 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $16K · 2021: $13K · 2022: $21K · 2023: $23K · 2024: $2,063 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Honoraria: $19K · Travel and Lodging: $1,771 · Food and Beverage: $79.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,350.50 |
| Honoraria | $19,200.00 |
| Travel and Lodging | $1,771.30 |
| Food and Beverage | $79.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $20,415.44 | 2019-2021 | |
| H. Lundbeck A S | $19,200.00 | 2023-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $16,003.68 | 2019-2022 | |
| Gw Pharma Limited | $12,683.59 | 2020 | |
| Acadia Pharmaceuticals INC | $12,125.00 | 2020-2022 | |
| Boehringer Ingelheim International Gmbh | $11,250.00 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,350.44 | 2023 | |
| F. Hoffmann-La Roche Ag | $8,812.50 | 2024-2025 | |
| Biogen, INC. | $4,208.50 | 2023 | |
| Eisai INC. | $3,625.00 | 2021 | |
| Orion Corporation | $1,142.00 | 2025 | |
| Sumitomo Pharma Co., LTD. | $1,000.00 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $937.50 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murray Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.